DE69839492D1 - Monoklonale antikörper zur apoptosis-induzierung - Google Patents

Monoklonale antikörper zur apoptosis-induzierung

Info

Publication number
DE69839492D1
DE69839492D1 DE69839492T DE69839492T DE69839492D1 DE 69839492 D1 DE69839492 D1 DE 69839492D1 DE 69839492 T DE69839492 T DE 69839492T DE 69839492 T DE69839492 T DE 69839492T DE 69839492 D1 DE69839492 D1 DE 69839492D1
Authority
DE
Germany
Prior art keywords
antibody
monoclonal antibodies
associated proteins
human integrin
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839492T
Other languages
English (en)
Inventor
Naoshi Fukushima
Shinsuke Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69839492D1 publication Critical patent/DE69839492D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69839492T 1997-09-11 1998-09-11 Monoklonale antikörper zur apoptosis-induzierung Expired - Lifetime DE69839492D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26485397 1997-09-11
PCT/JP1998/004118 WO1999012973A1 (fr) 1997-09-11 1998-09-11 Anticorps monoclonal induisant l'apoptose

Publications (1)

Publication Number Publication Date
DE69839492D1 true DE69839492D1 (de) 2008-06-26

Family

ID=17409137

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839492T Expired - Lifetime DE69839492D1 (de) 1997-09-11 1998-09-11 Monoklonale antikörper zur apoptosis-induzierung

Country Status (14)

Country Link
US (1) US20030157100A1 (de)
EP (1) EP1035132B1 (de)
KR (2) KR20010023866A (de)
CN (1) CN1198845C (de)
AT (1) ATE395362T1 (de)
AU (1) AU740225B2 (de)
CA (1) CA2303072A1 (de)
DE (1) DE69839492D1 (de)
HU (1) HUP0003513A3 (de)
NO (1) NO20001238L (de)
PL (1) PL339265A1 (de)
RU (1) RU2212413C2 (de)
SK (1) SK3232000A3 (de)
WO (1) WO1999012973A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006748A1 (fr) * 1993-09-03 1995-03-09 Chugai Seiyaku Kabushiki Kaisha Anticorps monoclonal permettant d'induire une apoptose
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
WO2000053634A1 (fr) * 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Fv monocatenaire induisant l'apoptose
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
TWI242043B (en) * 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
WO2001079494A1 (fr) * 2000-04-17 2001-10-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agonistes
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
AU1091702A (en) * 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded tpo agonist antibody
CN1308447C (zh) * 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
AU2002210918B2 (en) * 2000-10-20 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
ATE391174T1 (de) 2000-10-20 2008-04-15 Chugai Pharmaceutical Co Ltd Modifizierter tpo-agonisten antikörper
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
DE60324700D1 (de) 2002-10-11 2008-12-24 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
US20070003556A1 (en) * 2003-03-31 2007-01-04 Masayuki Tsuchiya Modified antibodies against cd22 and utilization thereof
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
EP1693385A4 (de) * 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd Humanisierter anti-cd47-antikörper
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
CA2548929A1 (en) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Cell death inducing agent
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
EP1870458B1 (de) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2-STRUKTURISOMERE
WO2006123724A1 (ja) * 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
JPWO2008007755A1 (ja) * 2006-07-13 2009-12-10 中外製薬株式会社 細胞死誘導剤
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
WO2009091547A1 (en) 2008-01-15 2009-07-23 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
PT3056514T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação de fagocitose mediada por cd47
US8951527B2 (en) 2008-08-07 2015-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
KR102338833B1 (ko) * 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
ES2786083T3 (es) 2012-12-12 2020-10-08 Arch Oncology Inc Anticuerpos terapéuticos CD47
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
BR112018005322A2 (pt) 2015-09-18 2018-12-11 Arch Oncology, Inc. anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
EP3484448A4 (de) 2016-07-13 2020-04-01 President and Fellows of Harvard College Antigenpräsentierende zellmimetische gerüste und verfahren zur herstellung und verwendung davon
EP3529276A4 (de) 2016-10-21 2020-06-17 Arch Oncology, Inc. Therapeutische cd47-antikörper
KR20200091901A (ko) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
IL312302A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for creating cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150262C (en) * 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
WO1995006748A1 (fr) * 1993-09-03 1995-03-09 Chugai Seiyaku Kabushiki Kaisha Anticorps monoclonal permettant d'induire une apoptose
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
WO1997032601A1 (fr) * 1996-03-06 1997-09-12 Chugai Seiyaku Kabushiki Kaisha Procede de criblage de substances induisant l'apoptose
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis

Also Published As

Publication number Publication date
NO20001238D0 (no) 2000-03-09
SK3232000A3 (en) 2000-09-12
AU9002898A (en) 1999-03-29
CN1276798A (zh) 2000-12-13
RU2212413C2 (ru) 2003-09-20
NO20001238L (no) 2000-05-11
EP1035132A1 (de) 2000-09-13
WO1999012973A1 (fr) 1999-03-18
AU740225B2 (en) 2001-11-01
ATE395362T1 (de) 2008-05-15
EP1035132B1 (de) 2008-05-14
EP1035132A4 (de) 2005-02-09
HUP0003513A3 (en) 2004-05-28
CA2303072A1 (en) 1999-03-18
KR20010023866A (ko) 2001-03-26
PL339265A1 (en) 2000-12-04
US20030157100A1 (en) 2003-08-21
CN1198845C (zh) 2005-04-27
HUP0003513A2 (hu) 2001-02-28
KR20040106585A (ko) 2004-12-17

Similar Documents

Publication Publication Date Title
DE69839492D1 (de) Monoklonale antikörper zur apoptosis-induzierung
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DE69635377D1 (de) Effiziente anreicherung und detektion von ausgesäten tumorzellen
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
PT733069E (pt) Antigenios ctla-8 de primata purificados e reagentes relacionados
ATE395413T1 (de) Antikörperkategorisierung auf der grundlage von bindungseigenschaften
DE68923027D1 (de) Antigene.
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
CU22615A1 (es) Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DK0742795T3 (da) Immunstimulerende monoklonale antistoffer
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
ATE202116T1 (de) Antikörperklassenspezifisches entstörungsreagenz
FR2660757B1 (fr) Procede d'identification ou de dosage de proteines et applications.
DE69622259D1 (de) Cd40 bindendes protein zur stimulierung der immunantwort
DE50009240D1 (de) Verwendung von Antikörpern zur Vakzinierung gegen Krebs
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
ATE266203T1 (de) Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum
CY1106349T1 (el) Συστηματα ανιχνευσης ανοσοπροσδιορισμου ιικου αντιγονου ηπατιτιδας c
DE69728897D1 (de) Saeugetierchemokine
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
ATE286596T1 (de) Chemische modifikation von antikörpern und antigenen
DE69026812D1 (de) Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern
GR890100219A (el) Ανθρωπινα μονοκλωνικα αντισωματα που ειδικα αναγνωριζουν κυτταραιου λυσσας κυτταρα που παραγουν τα ιδια, διαμορφωσεις που περιε χουν τα ιδια και παραγωγη ολων αυτων.
ES2141679A1 (es) Aplicacion de un inmunoensayo visual para la identificacion de la enfermedad celiaca utilizando como antigeno gliadinas de trigo.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition